Table 3.
Correlation of MSI status according to the clinicopathological data and RAS, PIK3CA, and BRAF mutations in our cohort.
| Clinicopathological parameters | MSI statusa | |
|---|---|---|
| MSS/MSI-L | MSI-H | |
| Age | p = 0.1853 | |
| ≥ 60 | 54 (43.9%) | 7 (70.0%) |
| < 60 | 69 (56.1%) | 3 (30.0%) |
| Sex | p = 0.7448 | |
| Male | 62 (50.4%) | 6 (60.0%) |
| Female | 61 (49.6%) | 4 (40.0%) |
| Tumor site | p = 0.009651 | |
| Right colon | 34 (27.6%) | 7 (70.0%) |
| Left colon | 89 (72.4%) | 3 (30.0%) |
| T stage | p = 0.004249 | |
| 1, 2 | 7 (5.7%) | 4 (40.0%) |
| 3, 4 | 116 (94.3%) | 6 (60.0%) |
| N stage | p = 0.002777 | |
| 0 | 27 (22.0%) | 7 (70.0%) |
| 1, 2 | 96 (78.0%) | 3 (30.0%) |
| M stage | p = 0.08775 | |
| 0 | 72 (58.5%) | 9 (90.0%) |
| 1 | 51 (41.5%) | 1 (10.0%) |
| Stage | p = 0.003935 | |
| 1, 2 | 20 (16.3%) | 6 (60.0%) |
| 3, 4 | 103 (83.7%) | 4 (40.0%) |
| Differentiationb | p = 1 | |
| Well/ Moderately | 102 (12.1%) | 9 (90.0%) |
| Poorly | 14 (87.5%) | 1 (10.0%) |
| Lymphatic invasionc | p = 0.7459 | |
| Absent | 41 (35.7%) | 4 (40.0%) |
| Present | 74 (64.3%) | 6 (60.0%) |
| Vascular invasionc | p = 0.09041 | |
| Absent | 70 (60.9%) | 9 (90.0%) |
| Present | 45 (39.1%) | 1 (10.0%) |
| Perineural invasionc | p = 0.02117 | |
| Absent | 59 (51.3%) | 9 (90.0%) |
| Present | 56 (48.7%) | 1 (10.0%) |
| Initial CEA level (blood)d | p = 0.01908 | |
| ≥ 4 | 60 (50.0%) | 9 (90.0%) |
| < 4 | 60 (50.0%) | 1 (10.0%) |
| RAS mutation | p = 0.04454 | |
| Absent | 54 (43.9%) | 8 (80.0%) |
| Present | 69 (56.1%) | 2 (20.0%) |
| PIK3CA mutation | p = 0.6935 | |
| Absent | 96 (78.0%) | 7 (70.0%) |
| Present | 27 (22.0%) | 3 (30.0%) |
| BRAF mutation | p = 0.3277 | |
| Absent | 119 (96.7%) | 9 (90.0%) |
| Present | 4 (3.3%) | 1 (10.0%) |
aA total of 12 patients have no MSI test result.
bA total of 14 patients have no available data .
cA total of 18 patients have no available data .
dThree patients have no available data.